Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Objective: To compare antidepressant-related adverse events (AEs), suicidality and AE-related discontinuation in double-blind, placebo-controlled trials of pediatric patients with OCD and anxiety disorders treated with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). Method: MEDLINE, PubMed, Web of Science, PsycINFO and Embase were searched for peer-reviewed, English-language articles from inception through March 1, 2019. We identified prospective, randomized, SSRI and SNRI studies in patients <18 years of age with OCD, generalized, separation or social anxiety disorders. AE rates were extracted and antidepressant-placebo differences examined using Bayesian hierarchical models (BHM). Then posterior estimates of relative risk (RR) were determined for each AE by medication class and disorder. Results: Data were included from 18 trials (2631 patients) and 7 medications (16 SSRI and 4 SNRI trials). Compared to placebo, SSRIs were associated with a greater likelihood of AE-related discontinuation (RR: 3.59, Credible Interval [CrI]: 0.019 to 0.067, p=0.0003), activation (RR: 2.39, CrI: 0.048 to 0.125, p=0.003), sedation (RR: 1.94, CrI: 0.035 to 0.157, p=0.002), insomnia (RR: 1.93, CrI: 0.040 to 0.149, p=0.001), abdominal pain (RR: 1.53, CrI: 0.032 to 0.164, p=0.005) and headache (RR: 1.24, CrI: 0.003 to 0.139, p=0.04). Activation was more common with SSRI (vs. SNRIs, RR: 1.32, CrI: 0.018 to 0.114, p=0.007). Neither SSRIs nor SNRIs were associated with treatment-emergent suicidality. Conclusions: In pediatric OCD and anxiety disorders, SSRIs as compared to placebo are associated with distinct adverse events (AEs) and greater AE-related discontinuation, although their tolerability does not differ between anxiety disorders and OCD. SSRIs are more likely than SNRIs to produce activation. Class-related AEs are important for clinicians to consider, particularly in light of data suggesting differences in class-related efficacy. While SSRIs are superior to SNRIs and the treatment of choice for anxiety, for youth who become activated on SSRIs, SNRIs might represent a good second choice given their reported efficacy and lower risk of activation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified
Higgins, J. P. T. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dyn204 · Cited by 995
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240
Brent, D. A., Emslie, G. J., Clarke, G. N., Asarnow, J., Spirito, A., Ritz, L., Vitiello, B., Iyengar, S., Birmaher, B., Ryan, N. D., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08070976 · Cited by 235
Research works printed but not linked: 41
- Alderman, 1998, Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy, J Am Acad Child Adolesc Psychiatry, 37, 386, 10.1097/00004583-199804000-00016 · DOI
- Bushnell, 2018, Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications, J Clin Psychiatry, 79, 10.4088/JCP.16m11415 · DOI · Paper page
- Strawn, 2015, A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder, J Am Acad Child Adolesc Psychiatry, 54, 283, 10.1016/j.jaac.2015.01.008 · DOI
- Rynn, 2007, Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials, Am J Psychiatry, 164, 290, 10.1176/ajp.2007.164.2.290 · DOI · Paper page
- Rynn, 2001, Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder, Am J Psychiatry, 158, 2008, 10.1176/appi.ajp.158.12.2008 · DOI · Paper page
- Watson, 2008, Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder, J Child Psychol Psychiatry, 49, 489, 10.1111/j.1469-7610.2007.01875.x · DOI · Paper page
- Geller, 2003, Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder, Am J Psychiatry, 160, 1919, 10.1176/appi.ajp.160.11.1919 · DOI · Paper page
- Varigonda, 2016, Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder, J Am Acad Child Adolesc Psychiatry, 55, 851, 10.1016/j.jaac.2016.07.768 · DOI · Paper page
- Reinblatt, 2009, Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents, J Child Adolesc Psychopharmacol, 19, 119, 10.1089/cap.2008.040 · DOI · Paper page
- Luft, 2018, Antidepressant-induced activation in children and adolescents: risk, recognition and management, Curr Probl Pediatr Adolesc Health Care, 48, 50
- Safer, 2006, Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents, J Child Adolesc Psychopharmacol, 16, 159, 10.1089/cap.2006.16.159 · DOI · Paper page
- Rynn, 2015, Child/adolescent anxiety multimodal study: evaluating safety, J Am Acad Child Adolesc Psychiatry, 54, 180, 10.1016/j.jaac.2014.12.015 · DOI · Paper page
- Reid, 2015, Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial, J Psychiatr Res, 71, 140, 10.1016/j.jpsychires.2015.10.006 · DOI
- Strawn, 2019, Switching selective serotonin reuptake inhibitors in adolescents with selective serotonin reuptake inhibitor-resistant major depressive disorder: balancing tolerability and efficacy, J Child Adolesc Psychopharmacol, 29, 250, 10.1089/cap.2018.0145 · DOI
- Connolly, 2007, Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders, J Am Acad Child Adolesc Psychiatry, 46, 267, 10.1097/01.chi.0000246070.23695.06 · DOI · Paper page
- Quintana, 2017, Bayesian analysis: using prior information to interpret the results of clinical trials, JAMA, 318, 1605, 10.1001/jama.2017.15574 · doi:10.1001/jama.2017.15574
- Lewis, 2018, Time for clinicians to embrace their inner bayesian?, JAMA, 320, 2208, 10.1001/jama.2018.16916 · DOI
- Gelman, 2014, Understanding predictive information criteria for Bayesian models, Stat Comput, 24, 997, 10.1007/s11222-013-9416-2 · DOI · Paper page
- McGlothlin, 2018, Bayesian hierarchical models, JAMA, 320, 2365, 10.1001/jama.2018.17977 · DOI
- Varigonda, 2015, Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors in pediatric major depressive disorder, J Am Acad Child Adolesc Psychiatry, 54, 557, 10.1016/j.jaac.2015.05.004 · DOI
- Riddle, 1992, Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder, J Am Acad Child Adolesc Psychiatry, 31, 1062, 10.1097/00004583-199211000-00011 · DOI · Paper page
- Aldrich, 2019, Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders, Front Pharmacol, 10, 99, 10.3389/fphar.2019.00099 · DOI · Paper page
- Mills JA, Strawn JR. Probabilistic biostatistics with Julia. In: JuliaCon Proceedings; 2019:1–6. Baltimore, Maryland, July 2019.
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Bezanson, 2017, Julia: a fresh approach to numerical computing, SIAM Review, 59, 65, 10.1137/141000671 · DOI · Paper page
- Ge, 2018, Turing: a language for flexible probabilistic inference, Proc Twenty-First Int Conf Artif Intell Stat, 84, 1682
- Moher, 2009, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement, Ann Intern Med, 151, 264, 10.7326/0003-4819-151-4-200908180-00135 · DOI · Paper page
- Birmaher, 2003, Fluoxetine for the treatment of childhood anxiety disorders, J Am Acad Child Adolesc Psychiatry, 42, 415, 10.1097/01.CHI.0000037049.04952.9F · DOI · Paper page
- Geller, 2001, Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial, J Am Acad Child Adolesc Psychiatry, 40, 773, 10.1097/00004583-200107000-00011 · DOI · Paper page
- Riddle, 2001, Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial, J Am Acad Child Adolesc Psychiatry, 40, 222, 10.1097/00004583-200102000-00017 · DOI · Paper page
- Geller, 2004, Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial, J Am Acad Child Adolesc Psychiatry, 43, 1387, 10.1097/01.chi.0000138356.29099.f1 · DOI · Paper page
- March, 1998, Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial, JAMA, 280, 1752, 10.1001/jama.280.20.1752 · DOI · Paper page
- Crawley, 2014, Somatic complaints in anxious youth, Child Psychiatry Hum Dev, 45, 398, 10.1007/s10578-013-0410-x · DOI · Paper page
- Alfano, 2007, Sleep-related problems among children and adolescents with anxiety disorders, J Am Acad Child Adolesc Psychiatry, 46, 224, 10.1097/01.chi.0000242233.06011.8e · DOI · Paper page
- Caporino, 2017, Sleep-related problems and the effects of anxiety treatment in children and adolescents, J Clin Child Adolesc Psychol, 46, 675, 10.1080/15374416.2015.1063429 · DOI
- Alfano, 2011, Objective sleep patterns and severity of symptoms in pediatric obsessive compulsive disorder: a pilot investigation, J Anxiety Disord, 25, 835, 10.1016/j.janxdis.2011.04.004 · DOI · Paper page
- Storch, 2008, Sleep-related problems in pediatric obsessive-compulsive disorder, J Anxiety Disord, 22, 877, 10.1016/j.janxdis.2007.09.003 · DOI
- Sevilla-Cermeño, 2019, Insomnia in pediatric obsessive–compulsive disorder: prevalence and association with multimodal treatment outcomes in a naturalistic clinical setting, Sleep Med, 56, 104, 10.1016/j.sleep.2018.12.024 · DOI
- Sharma, 2016, Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports, BMJ, 352
- Strawn, 2017, Placebo response in pediatric anxiety disorders: results from the Child/Adolescent Anxiety Multimodal Study, J Child Adolesc Psychopharmacol, 27, 501, 10.1089/cap.2016.0198 · DOI · Paper page
- Dobson, 2016, Placebo response in pediatric anxiety disorders: implications for clinical trial design and interpretation, J Child Adolesc Psychopharmacol, 26, 686, 10.1089/cap.2015.0192 · DOI · Paper page
Cited by
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2903 · Cited by 521
Self-citationResearch Review: Pediatric Anxiety Disorders—What Have We Learnt in the Last 10 Years?
Strawn, J. R., Lu, L., Peris, T. S., Levine, A., & Walkup, J. T. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13262 · Cited by 168
Self-citationPharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Advances in Pharmacotherapy for Pediatric Anxiety Disorders
Nicotra, C. M., & Strawn, J. R. (2023) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2023.02.006 · Cited by 16
Self-citation
Metadata
- Authors
- Mills, J. A., & Strawn, J. R.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 59
- Issue
- 11
- Pages
- 1240-1251
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W2984602026
- Cited by
- 56
- References
- 18
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Institute of Child Health and Human Development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.